ZMB Research Program Oncology
ZMB Research Program
Oncology
Oncology
The concept of this research programme is to understand fundamental processes in tumor biology in order to develop novel molecularly defined and rationally applied cancer treatments. Participating researchers from biology, experimental and clinical medicine study tumors as "biological systems" and so called "neo-organs". A large variety of approaches, experimental systems and methodologies are in place to analyse many aspects of tumor development, growth, progression and tumor cell migration.
A first focus lies on the investigation of the behaviour of malignant cells, their signalling interactions, cell death (apoptosis) and proliferation rates, as well as changes in their differentiation program. Moreover, as most drug targets are proteins, researchers in this program focus on the molecular analysis of cancer-relevant proteins. Protein function is linked to expression levels, specific subcellular localization, interaction with other proteins and post-translational modifications. These events contribute to the various functional properties that are important for the malignant transformation of cells.
A second focus lies on the investigation of the molecular details of migration and metastasis of tumor cells, as well as cellular responses to cell damage. In addition, in cooperation with researchers from the Program on Immunology and Infectious Diseases, the interactions between the immune system and tumours are of particular interest.
Contact
Prof. Dr. Barbara Grünwald
Current Selected Publications since 2025
-
Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinomaIn: Nature Communications, Vol. 17, 2026, Nr. 1, 1476DOI (Open Access)
-
Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal CancerIn: Clinical Cancer Research, Vol. 32, 2026, Nr. 5, pp. 938 – 946DOI (Open Access)
-
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010) : A randomised, double-blind, phase 3 studyIn: The Lancet Oncology, Vol. 27, 2026, Nr. 3, pp. 327 – 339DOI (Open Access)
-
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunityIn: Cancer Cell, Vol. 43, 2025, Nr. 2, pp. 269 – 291.e19DOI (Open Access)
-
Adjuvant nivolumab and relatlimab in stage III/IV melanoma : the randomized phase 3 RELATIVITY-098 trialIn: Nature Medicine, Vol. 31, 2025, Nr. 12, pp. 4301 – 4309DOI (Open Access)
-
Advances and challenges in precision imagingIn: The Lancet Oncology, Vol. 26, 2025, Nr. 1, pp. e34 – e45DOI, Online Full Text (Open Access)
-
Approaches to stable isotope tracing and in vivo metabolomics in the cancer clinicIn: The EMBO Journal, Vol. 44, 2025, Nr. 12, pp. 3303 – 3306DOI (Open Access)
-
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialIn: Nature Medicine, Vol. 31, 2025, Nr. 1, pp. 152 – 164DOI (Open Access)
-
CSF1R⁺ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphomaIn: Cancer Cell, Vol. 43, 2025, Nr. 8, pp. 1476 – 1494.e10DOI (Open Access)
-
Clinical validation of droplet digital PCR assays in detecting BRAFV⁶⁰⁰-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD) : A biomarker analysis from a double-blind, randomised phase 3 trialIn: The Lancet Oncology, Vol. 26, 2025, Nr. 5, pp. 641 – 653
-
Common origin and somatic mutation patterns of composite lymphomas and leukemiasIn: Leukemia, Vol. 39, 2025, Nr. 8, pp. 1960 – 1971DOI (Open Access)
-
Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistanceIn: Nature Communications, Vol. 16, 2025, Nr. 1, 5387DOI (Open Access)
-
Discordance, accuracy and reproducibility study of pathologists’ diagnosis of melanoma and melanocytic tumorsIn: Nature Communications, Vol. 16, 2025, Nr. 1, 789DOI (Open Access)
-
ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancerIn: Nature Communications, Vol. 16, 2025, Nr. 1, 10983DOI (Open Access)
-
Facts and Hopes in Neoadjuvant Immunotherapy Combinations in Resectable Non-Small Cell Lung CancerIn: Clinical Cancer Research, Vol. 31, 2025, Nr. 5, pp. 801 – 807
-
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced MelanomaIn: The New England Journal of Medicine, Vol. 392, 2025, Nr. 1, pp. 11 – 22DOI, Online Full Text (Open Access)
-
G-CSF/NAMPT signaling drives neutrophil dysfunction and enhances bacterial infection susceptibility in cancer patientsIn: Nature Communications, Vol. 16, 2025, Nr. 1, 11137DOI (Open Access)
-
Gemtuzumab ozogamicin in first-line treatment of CBF-AML : Insights from a retrospective multi-center analysisIn: Leukemia, Vol. 39, 2025, Nr. 9, pp. 2174 – 2180DOI (Open Access)
-
Genetic lesions in nodular lymphocyte-predominant Hodgkin lymphoma and T cell/histiocyte-rich large B-cell lymphoma identified by whole genome sequencingIn: Leukemia, Vol. 39, 2025, Nr. 9, pp. 2215 – 2225DOI (Open Access)
-
Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment : A Consensus ReviewIn: JAMA Oncology, Vol. 11, 2025, Nr. 12, pp. 1527 – 1537
-
High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non-Small Cell Lung Cancer in PatientsIn: Cancer Discovery, Vol. 15, 2025, Nr. 4, pp. 702 – 716DOI (Open Access)
-
High-resolution spatial transcriptomics uncover epidermal-dermal divergences in Merkel cell carcinoma : Spatial context reshapes the gene expression landscapeIn: Oncogene, Vol. 44, 2025, Nr. 47, pp. 4615 – 4625DOI (Open Access)
-
Hypoxic-ischemic brain injury in neonatal mice sequentially recruits neutrophils with dichotomous phenotype and functionIn: Nature Communications, Vol. 16, 2025, Nr. 1, 9696DOI (Open Access)
-
Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progressionIn: Nature Communications, Vol. 16, 2025, Nr. 1, 11280DOI (Open Access)
-
Mitochondrial Glutathione Import Enables Breast Cancer Metastasis via Integrated Stress Response SignalingIn: Cancer Discovery, Vol. 15, 2025, Nr. 12, pp. 2437 – 2449DOI, Online Full Text (Open Access)
-
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancerIn: Nature Medicine, Vol. 31, 2025, Nr. 8, pp. 2755 – 2767DOI (Open Access)
-
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice : An international surveyIn: The Lancet Oncology, Vol. 26, 2025, Nr. 1, pp. 12 – 14
-
Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancerIn: Nature Communications, Vol. 16, 2025, Nr. 1, 335DOI (Open Access)
-
Subgrouping germinal center-derived B-cell lymphomas based on machine learning-deduced DNA methylation modulesIn: Leukemia, Vol. 39, 2025, Nr. 4, pp. 967 – 971DOI (Open Access)
-
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based ChemotherapyIn: The New England Journal of Medicine, Vol. 393, 2025, Nr. 4, pp. 349 – 361
-
The molecular blueprint of targeted radionuclide therapyIn: Nature Reviews Clinical Oncology, Vol. 22, 2025, Nr. 11, pp. 869 – 894
-
Transcription factor switching drives subtype-specific pancreatic cancerIn: Nature Genetics, Vol. 57, 2025, Nr. 12, pp. 3016 – 3026DOI (Open Access)
-
Tumour tissue : Heterogeneous, but not disorderedIn: Nature Reviews Cancer, Vol. 25, 2025, Nr. 11, pp. 821 – 822
-
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047In: Clinical Cancer Research, Vol. 31, 2025, Nr. 17, pp. 3702 – 3714DOI (Open Access)
-
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trialIn: Nature Communications, Vol. 16, 2025, Nr. 1, 5919DOI (Open Access)
-
[⁶⁸Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation : A single-centre, single-arm, interventional, phase 2 trialIn: The Lancet Oncology, Vol. 26, 2025, Nr. 9, pp. 1204 – 1214DOI (Open Access)
-
msiFlow : automated workflows for reproducible and scalable multimodal mass spectrometry imaging and microscopy data analysisIn: Nature Communications, Vol. 16, 2025, Nr. 1, 1065DOI (Open Access)